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IN a previous communication (Guimaraes and Lamerton, 1956) upon the late
effects of Thorotrast administration in mice, it was suggested that the apparent
carcinogenic effect of Thorotrast might be related in some way to its physical
properties rather than to its purely radioactive properties. The object of the
present investigation was to follow up this suggestion by employing a colloidal
contrast medium which was similar to Thorotrast in its distribution and other
properties but which was at the same time entirely non-radioactive, and to
compare the resulting tissue damage and tumour incidence.
The ideal product for this purpose would be derived from a non-radioactive
thorium isotope, but since no such isotope is known, attention was turned to the
other elements in Group IV A of the Periodic Table, and in particular to hafnium,
the closest analogue of thorium. Our attempts to produce a concentrated hafnium
oxide sol were only partially successful. Owing to the relative scarcity and cost of
hafnium salts further work was carried out using zirconium salts since these are
virtually identical from the point of view of their chemical properties.
A concentrated zirconium oxide sol was prepared (hereafter called Zircono-
trast) and this material was well tolerated when given to mice by intravenous
injection. This contrasts with a report (Shapiro, 1955) that whereas soluble
zirconium salts are relatively non-toxic, a colloidal zirconium oxide preparation
consistently caused death from pulmonary infarction when given intravenously to
rabbits and guinea-pigs. In view of this finding we thought it worth while to
include details of our method of preparing Zirconotrast.
The present article concerns the results of a comparative study of the effects
resulting from intravenous injection of Thorotrast and Zirconotrast into small
groups ofmice which were observed radiologically over a period oftime and finally
killed 8-17 months later for histological studies.
METHODS
Zirconotrast
The preparative scheme conisists essentially of three parts. First, formation of
a dilute zirconium oxide sol by hydrolysis at the boiling point of a solution of
zirconyl chloride (Robinson and Ayres, 1933). Second, neutralisation of the acid
sol without the formation of locally high pHs which cause gelling, and third,
concentration of the sol after the addition of dextrin as a stabilising agent. Dextrin
was chosen since this is used in the preparation of Thorotrast (Zellmann, 1933).
Twenty g. of z rconium oxychloride (ZrOCl2 . 8 H20) are dissolved in aboutEFFECTS OF THOROTRAST AND ZIRCONOTRAST
100 ml. distilled water, filtered through paper (Whatman 531) and the volume
made up to 800 ml. This solution is boiled under refiux and after approximately
25 hours the absorption at 680 miu. is measured at intervals (1 or 2 hours) using
a Uvispek spectrophotometer (Hilger and Watts). When the absorption
reaches a density of 0 45 for a 1 cm. light path (circa 30 hours) boiling is stopped.
On standing, a small amount of fine particulate matter settles out, but the sol is
stable for at least two weeks, as indicated by constant absorption readings during
this time. 400 ml. of this stock sol, pH 1X2, is then evaporated down to 200 ml.,
allowed to cool and 200 ml. of a weak base anion exchange resin (De-Acidite
G-Permutit Co.,) in the base form added with stirring. After 10 minutes stirring
is stopped and the pH measured, with repetition at suitable intervals until a pH
value of 4X7-4X8 is reached. Immediately the sol is decanted through a glass
wool filter and the resin washed twice with water by decantation (100 ml. each
wash), the washings being added to the main filtrate.
The sol is now stabilised by addition of a saturated dextrin solution sufficient
to give a final concentration, after further evaporation, of approximately 14 per
cent w/v. The dextrin solution is prepared by stirring a large excess of dextrin
puriss with distilled water for 2 hours, followed by centrifugation. The super-
natant is largely clear and has a dextrin concentration of approximately 13 per
cent w/v. The sol with added dextrin is evaporated down to about 40 ml. with
rapid stirring (stainless steel paddle), the pH now being 3-2. It should be noted
that in the case of concentrated sols a constant pH reading was only obtained after
at least 10 minutes immersion of the electrodes. The resin treatment outlined
above is repeated, but using 15 ml. of De-Acidite G in the base form and 40 ml. of
partially concentrated sol, with a mixing time of 8 minutes. The pH of the sol
after filtration is 6X15 and with the washings is 6-6. 25 ml. 0X2 per cent methyl p-
hydroxy benzoate is added as sterilising agent, and the mixture evaporated down
to a final volume of 25 ml., the pH now being 6-3. The sol is finally passed through
a sintered glass filter (porosity 4) and loaded into sterilised bottles.
The concentration ofzirconium in the sol was determined in the following way:
0-3 ml. aliquot of the sol was boiled with 5 ml. dilute hydrochloric acid, and after
dilution to 20 ml. a small excess of sodium hydroxide was added and the mixture
boiled for an hour, the evaporation loss being replenished at intervals. The fine
white granular precipitate was collected on filter paper (Whatman 542), washed
well with water, dried and ignited in a tarred platinum dish. The weight obtained
was taken as the weight of zirconium oxide in the sample aliquot.
The Zirconotrast used in the experimental work reported in this paper had the
following composition:
Zirconium dioxide 13 per cent w/v
Dextrin 17 per cent w/v
Methyl p-hydroxy benzoate 0 2 per cent
pH 6 3
Particle size
Electron micrographs indicate (Fig. 1 and 2), on the assumption that the partic-
les are spherical, that 90 per cent of the weight of zirconium oxide is contained in
particles with diameters ranging from 50-100 mp. It should be noted that bv
comparison, Thorotrast particles are, on average, 5-6 times smaller and in addition
have a more irregular and angular shape. This difference follows from the modes
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ofpreparation of the two sols. For Zirconotrast, this involved accretion of ultra-
micro particles in solution, and for Thorotrast, dispersion of a solid phase, thorium
dioxide, obtained by thermal decomposition of thorium oxalate.
EXPERIMENTAL
Fifty-two male Schofield mice between 30-35 g. were divided into 3 groups
as follows:
Group A.-16 mice given 041 ml. of Thorotrast intravenously.
Group B.-18 mice given 041 ml. of Zirconotrast intravenously.
Group C.-18 normal, uninjected mice as controls.
All the 3 groups were maintained on Aberdeen rat cake as in the previous experi-
ments and water was given ad libitum. Groups A and B were radiographed at
intervals to confirm the presence and persistence of the contrast materials.
There were no immediate deaths following the injection of the Thorotrast or
the Zirconotrast. The first death occurred from broncho-pneumonia in the
Zirconotrast group at 8 months. The majority of the mice in all 3 groups sur-
vived for over a year. The experiment was terminated at 18 months by killing
all the remaining animals. These mice were autopsied and histological studies
made of the liver, spleen, lungs, kidneys, lymph nodes, testis and in some cases,
the bone marrow. The number of survivors in each group at the end of the
experiment is indicated in Table I.
EXPLANATION OF PLATES
FIG. 1. Electron micrograph of Zirconotrast particles, magnification x 50,000. By courtesy
of Dr. E. H. Mercer, Chester Beatty Research Institute, London, S.W.3.
FIG. 2. Electron micrograph of Thorotrast particles, magnification x 50,000. By courtesy
of Dr. E. H. Mercer, Chester Beatty Research Institute, London, S.W.3.
FIG. 3.- A small superficial hepatoma in the liver of a 16 month old, control mouse. H & E
x20.
FIG. 4. Histological appearance of the liver of a mouse given 0-1 ml. Thorotrast 17 months
previously, showing a hepatoma (right half offield). Note the Thorotrast aggregates in the
normal liver whereas the hepatoma contains none. Also the absence of any form of tissue
reaction. H. & E. x 20.
FIG. 5. The appearance of the liver of a mouse 17 months after a dose of 0-1 ml. Thorotrast.
Part of a large, soft and haemorrhagic tumour, 2-3 x 2-0 x 1-2 cm. occupying the left lobe.
The Thorotrast aggregates are confined to one area of the liver. The remainder consists of
abnormally orientated liver cords with areas of necrosis and numerous blood-filled spaces,
several of which contain ante-mortem thrombus. H. & E. x 12.
FIG. 6.-Radiograph of the mouse in Fig. 5. Note the absence of Thorotrast from the centre
of the liver tumour.
FIG. 7.-Subcutaneous sarcoma on the tail of a mouse given an intravenous injection of 0-1
ml. Thorotrast in this region 13 months previously. Autoradiography ofthis tumour showed
alpha-tracks only at the edge of the tumour in the region of macrophages. Some tracks
were present in the bone marrow. H. & E. x 15.
FIG. 9. The margin between an area of normal liver, to the right, and a small hepatoma in a
mouse 17 months after injection of 0-1 ml. of the Zirconotrast preparation. Note the
Zirconotrast aggregates and the absence of reaction around them. H. & E. x 105.
FIG. 10. Radiograph of the mouse whose liver tumour is depicted in Fig. 11.
FIG. 11. Part of a large, soft haemorrhagic tumour, 3 x 2 cm., in the left lobe of the liver of
a mouse which died 17 months after receiving 0-1 ml. Zirconotrast. At autopsy a large
amount ofblood and blood clot was present in the peritoneal cavity. Note the large, blood-
filled spaces similar to those seen in Fig. 5. The remainder of the section shows areas of
hepatomatous change. H. & E. x 18.
64BRITISH JOIuRNAL OF CANCER.
Bensted and Crookall.
VOl. XVII, NO. 1.
h.
... il
L.BRITISH JOURNAL OF CANCER.
3 4
6
5
Bensted and Crookall.
VOl. XVII, NO. 1.
s.BRITISH JOURNAL OF CANCER.
A 7
:^ 4
t..
/
:-
.0
ii
Bensted and Crookall.
VOl. XVII, NO. 1.
.EFFECTS OF THOROTRAST AND ZIRCONOTRAST
TABLE I.-Survival ofExperimental Mice
Number of
Original survivors at
number termination Per cent
Group of mice of experiment survivors
Thorotrast . 16 . 6 . 37
Zirconotrast . 18 . 4 . 22
Control . 18 . 9 . 50
Histological Observations
A. Control
Autopsy records and tissues were available on 14 of the original 18 mice.
Five of the 18 mice showed liver tumours (Fig. 3) and 10 showed pulmonary
adenomata. Three of the 18 mice showed leukaemic infiltration of the tissues.
B. Thorotrast group
Autopsy records and tissues were available on 13 out of the original 16 mice.
In the liver, the histological changes were similar to those described previously
(Guimaraes, Lamerton and Christensen, 1955: Guimaraes and Lamerton, 1956).
The Thorotrast aggregates frequently abutted onto a hepatic vein into which
they could very readily have ruptured, thus affording a meanswhereby the Thoro-
trast could be further distributed throughout the body at a late interval after the
original injection.
In this group there were 5 liver tumours which were classified as hepatomata,
onefound at 12 months andfour at 17 months at the termination ofthe experiment
(Fig. 4). One of these latter mice, whose liver contained a large, soft, haemor-
rhagic tumour, 2-3 x 2 x 1-2 cm., showed histological changes suggestive of a
haemangio-endothelioma of the liver. (Fig. 5). These changes consisted of
numerous large irregular spaces, some filled with blood cells and others with a
reticular meshwork of eosinophilic, amorphous material. Those spaces which
contained blood could be seen to possess a definite endothelial lining but without
any marked proliferative changes being evident. In some of them ante-mortem
thrombus material was present. There were also some areas of parenchymal
necrosis and interstitial fibrosis. In this case, the spleen was slightly enlarged
and on histological examination, showed several large blood filled spaces some of
which contained ante-mortem thrombus. The interpretation of the structure of
the endothelial lining of these spaces in the spleen was difficult owing to post-
mortem change. The histological changes in the liver and spleen were very similar
to those which have been described in cases of haemangio-endothelioma (Roth,
1957). In this particular case the most malignant changes appeared to be in the
spleen in which organ the tumour may be regarded as originating. Fig. 6 is a
post-mortem radiograph of the mouse showing the Thorotrast present in the
spleen and liver but only in the periphery of the latter.
Three examples of a lymphatic type ofleukaemia were observed, characterised
by enlargement of the spleen and lymph nodes and with extensive leukaemic
infiltration of other organs. One ofthese leukaemias was present in a mouse with
a hepatoma.
One mouse, killed at 13 months, showed a firm subcutaneous swelling of the
tail at the site of the intravenous injection of Thorotrast. Histological examina-
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tion showed that this was a fibrosarcoma (Fig. 7). Presumablv this tumour had
resulted from the escape of a small amount of Thorotrast into the extra-vascular
tissues. An autoradiograph of this tumour showed that there was practically no
Thorotrast in the tumour itself although Thorotrast could be detected in the
surrounding tissue and in the bone marrow of the tail vertebrae.
Seven mice showed pulmonary adenomata which were frequently subpleural
in situation.
(1. Zirconotrast
Autopsy records and tissues were available on 17 of the original 18 mice. The
mice in this group failed to gain weight as rapidly as the Thorotrast and control
mice whose mean weight curves were very similar (Fig. 8). There was also a
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FIG. 8. The mean weight curves of the three groups of mice. Note the close similarity
between the Thorotrast and Control groups whereas the Zirconotrast group fails to
gain weight at the same rate as the other two groups.
considerably higher mortality in this group from about the 15th month on-
wards, 5 of the 8 deaths being the result of lung infections.
Histological examination of the tissues of the mice in this group revealed the
presence of aggregates ofZirconotrast in the liver which could not be distinguished
from Thorotrast aggregates. Cellular changes in the liver were similar in ap-
pearance to those observed in mice which had received Thorotrast in the present
experiments (Fig. 9).
Five of the 17 mice which had received Zirconotrast showed hepatomas, 4
dying at 16, 17, 17 and 17 months and 1 being killed at 17 months. One of the
mice which died, showed a large soft mass, 3 x 2 x 2 cm., in the left lobe of the
liver together with fresh blood and blood clot in the peritoneal cavity (Fig. 10).
Histological examination of the liver was rather unsatisfactory owing to post-
mortem change but there was clear evidence ofhepatomatous change amongst the
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parenchymal cells associated with large sinusoidal spaces filled with blood and
small areas of parenchymal necrosis (Fig. 11). This picture was similar in several
respects to that seen in one of the Thorotrast group of mice where a diagnosis of
haemangio-endothelioma was made, though in the Zirconotrast injected mouse
the diagnosis was less certain. The spleen in this mouse did not show any changes
suggestive of a haemangio-endothelioma but the follicles were hyperplastic. This
evidence, together with the presence of collections of small, darkly staining cells
in the liver and kidney, suggested that this mouse might well also be leukaemic.
Four other mice showed clear evidence of leukaemic infiltration of the tissue
and a further 4 mice showed pulmonary adenomata.
Tumour Incidence
The incidence of liver tumours (hepatomata), pulmonary adenomata and of
leukaemia in the three groups is shown in Table II.
TABLE II.-Incidence of Leukaemia, Pulnonary Adenomas and Hepatomas
Number
Original Number Number with Number
number examined with pulmonary with
Group of mice at autopsy leukaemia adenomas hepatomas
Control 18 14 3 . 10 5
Thorotrast 16 13 3 7 5a
Zirconotrast 18 . 17 . 4 4 5b
(1-including one hepatoma associated with a haemangio-endothelioma.
b--including one hepatoma associated with a possible haemangio-endothelioma.
DISCUSSION
Despite the small number ofmice used in this study, one conclusion would seem
to be that, in so far as the incidence of liver tumours in the three groups is
concerned, there is no marked difference between them. The relatively high (35
per cent) incidence ofliver tumours in the control mice used in the present experi-
ment is very much higher than the 4 per cent incidence reported by Guimaraes
and Lamerton (1956) using mice obtained from the same colony. However, it
should be pointed out that in the work reported by these authors, all the mice had
been killed by 12 months. In the present experiment no liver tumours were
observed in the 3 control mice which were killed or which died before 16 months.
One liver tumour was observed at 16 months and the other at the termination of
the experiment at 18 months.
There may be a similar explanation for the relatively high incidence of pul-
monary adenomata in the control and Thorotrast mice. In the Zirconotrast
group, the relatively high early mortality may have reduced the number of
potential candidates which might have developed this lesion. There is no clear
explanation at present of the apparently high morbidity amongst the Zirconotrast
mice and also their failure to gain weight at the same rate as the other two groups.
One possible explanation of these differences may lie in the relative size of the
particles which were administered. Shapiro (1955) described early deaths from
pulmonary infarction with multiple pulmonary emboli. In his case, although the
particles averaged 3-5 ,t when the suspension was first prepared, they tended to
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settle out upon standing and aggregates measuring as much as 15-150
, could
result. Although we do not have any information at present on the degree of
aggregation of the Zirconotrast particles in plasma it is possible that some of
these aggregates were large enough to have caused small areas of pulmonary
infarction which subsequently may have become the sites of pneumonic infection
and collapse. The electron micrographs certainly demonstrate the marked
difference in size between the Thorotrast and Zirconotrast particles.
It has often been inferred from clinical and experimental Thorotrast studies
that the apparent carcinogenic action of Thorotrast could be related either to its
direct radiation effects (Tesluk and Nordin, 1955; Horta, 1956) or indirectly to
the tissue damage and repair which result from the radiation. In the present
experiment there was no evidence of reparative processes at work either in the
Thorotrast or Zirconotrast groups. Guimaraes and Lamerton (1956) also failed
to observe such changes.
The experimental results indicate that, although the incidence ofliver tumours
inall threegroups was similar, there was definite evidence in the Thorotrast group,
but only suggestive evidence in the Zirconotrast group, of the occurrence of a
relatively rare type of mesodermalliver tumour, the haemangio-endothelioma
which has been suggested by Looney (1960) on the basis of clinical and experi-
mental material, as being almost a "Thorotrast specific " tumour. Looney
(1960) is at the same time careful to draw attention to the earlier observations of
Roth (1957) who reported three tumours of this type in a group of 25 vineyard
workers with chronic arsenic poisoning and who concludes that a distinction be-
tween these tumours and those associated with Thorotrast could not be made.
On this evidence, then, it would seem that it is not necessarily the radioactivity of
Thorotrast which is responsible for its apparent carcinogenic effect. If these
rare tumours of theliver are still to be regarded as "Thorotrast specific " then
some other non-radioactive physical property of Thorotrast such as its colloidal
or its chemical nature should be considered.
The observations of Upton, Furth and Burnett (1956) suggest, however, that
it is not necessarily the colloidal nature of a substance which may render it car-
cinogenic as far as theliver is concerned. These workers were able to produce
hepatomas in1 monthold RF mice with radioactive gold, butwhen another group
of RF mice was given similar amounts of radioactive colloidal gold but with the
difference that the radioactivity had been allowed to decay to negligible levels for
aperiod of 60days, they then failed to observe any liver tumours after a period of
observation of 21 months.
The possibility still remains of some chemical factor which may be responsible
for the production of the liver changes. Generally a chemical factor might be
expected to produce some initial degree ofliver necrosis followed by reparative
changes which, in theliver, are associated with varying degrees of cirrhosis. Some
observers consider cirrhosis to be an important contributory factor in the produc-
tion of haemangio-endotheliomata of theliver. Baker, Paget and Davson (1956)
described three cases ofhaemangio-endotheliomata of the liver in adult men and
reviewed 25 other cases from the literature. In 2 of their cases and in 9 of the
other cases, cirrhosis was a prominent feature.
Horta (1956) in describing a case ofangioblastic sarcoma ofthe liver following
Thorotrast administration considered that the accompanying cirrhosis was the
direct result ofThorotrast. Jacobson and Rosenbaum (1938) and Cassel, Ruffin,
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Reeves and Stoddard (1951) also described cirrhotic changes in the livers of some
of their patients who had received Thorotrast for diagnostic purposes from 5 to
17 years previously. It has alwavs to be remembered, of course, that some form
ofpre-existing liver damage may be the reason for the use ofThorotrast in the first
place. Experimental studies, however, do not appear to support the idea of
liver damage and cirrhosis following Thorotrast administration. Guimaraes,
Lamerton and Christensen (1955) and Guimaraes and Lamerton (1956) failed to
observe liver damage and cirrhosis in their mice. There was evidence of liver
damage and fibrosis in only one of the Thorotrast injected mice in the present
experiment. These observations appear to be in agreement with those ofFrankel,
Patek and Bernick (1962) who gave intravenous injections of Thorotrast (0.125
ml. per 100 g. body weight) to male Holtzman rats and followed them at autopsy
at monthly intervals up to 10 months. They did not report the development of
liver damage or fibrosis at this dose level of Thorotrast.
While the experimental results presented here are inconclusive with regard to
the mechanism of the carcinogenic action of Thorotrast, the present work utilising
a non-radioactive analogue of Thorotrast provides a new approach to the problem.
Further experiments with different strains of mice and with wider ranges of
administered dose will provide useful information concerning this problem.
SUMMARY
A comparison has been made of the late effects of Thorotrast and a non-radio-
active colloidal contrast medium, Zirconotrast, in mice. There was no significant
difference in the incidence ofliver tumours between these two groups and a group
of control mice. One haemangio-endothelioma was seen in the Thorotrast group
and a possibly similar tumour observed in the Zirconotrast group. The details of
preparation of the Zirconotrast are also given.
We are grateful to Professors W. V. Mayneord and L. F. Lamerton for their
interest and encouragement in this study, and to Dr. W. Anderson for his helpful
advice on the preparation of the Zirconotrast.
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